Navigation Links
Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others
Date:9/23/2010

and resources if we are to see better prevention and treatment in more areas. And across all areas, researchers need to take into account the effects of both biologically determined sex differences and socially determined gender differences as a routine part of conducting research."

Historically, researchers recruited women to clinical studies less often than men in part because of ethical concerns about potential fetal exposure to experimental substances; the flux of hormones in women's bodies, which could complicate studies; and the assumption that results of studies on men could be extrapolated to women. However, trial results were not necessarily applicable or consistently applied to women, as demonstrated by the unequal use of stents, beta blockers, and cholesterol-lowering drugs to treat heart disease in women. Moreover, the symptoms and courses of diseases in males do not always correspond to what happens in females. Inadequate research focus on women's health issues was first comprehensively documented in 1985, which led to a transformation in government and public support of women's health research and in related policies and regulations.

Requirements for researchers to enroll women in clinical trials have enabled many advances. Yet the full benefit of increased participation by women has not been realized because researchers do not routinely analyze and report results separately for women and men, the committee observed. This limits the breadth and depth of clinical information that could facilitate more effective interventions and treatments for women. Journal editors should adopt a guideline that all papers reporting outcomes of clinical trials must present data on men and women separately unless a trial focuses on a sex-specific condition such as prostate cancer, the report says. In addition, the U.S. Food and Drug Administration should enforce companies' compliance with requirements to provide sex-specific data on the eff
'/>"/>

Contact: Christine Stencel
news@nas.edu
202-334-2138
National Academy of Sciences
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Benefits of increased health care transparency hinge on reliable and valid information, says ACP
2. Study finds an increased risk of death in men with insomnia and a short sleep duration
3. Drug coverage under Medicare leads to increased use of antibiotics
4. Oral contraceptive use associated with increased risk of breast cancer
5. Mayo Clinic Proceedings: Sexual abuse survivors have increased of psychiatric disorders
6. Women with gestational diabetes have increased risk of recurrence in subsequent pregnancies
7. Clothing4all WOWs Yet Again With Customer Appreciation and Increased Sales
8. Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization
9. Counseling increased mammography use among low-income women with health insurance
10. Minor kidney damage in people with type 1 diabetes leads to increased mortality
11. Children with special needs are at increased risk for oral disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... free of blood and protein soils where it ... Miele, the world’s leading manufacturer of premium domestic ... to verifying surgical instruments are effectively cleaned. The ... of surgical instruments immediately after processing. After 3 ...
(Date:7/29/2014)... is in principle suitable to find out which preferences ... it in health economic evaluations, some (primarily methodological) issues ... of a pilot project by the German Institute for ... Analytic Hierarchy Process (AHP), CA is the second method ... Summarize outcome-specific results to an overall value ...
(Date:7/29/2014)... new lung is grown for a patient in need, using ... injection of replacement cells will enable a patient to self-heal ... ALERT: For audio and video of Dr. Keller and Jorge ... Mayo Clinic News Network . , Regenerative ... gift from Jorge and Leslie Bacardi of the Bahamas will ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent S. Greenawalt ... (FCA) National Convention and Expo, speaking on Ground Force ... on Thursday, August 20th at the Hyatt Regency in ... impact functional foot orthotics, like Foot Levelers Stabilizing Orthotics, ... fasciitis, and hammertoes. , Invented by a chiropractor in ...
(Date:7/29/2014)... July 29, 2014 1WorldSync announces ... leading healthcare suppliers will utilize the Global Data ... information network to share product information with the ... trading partners across their global supply chain. Holger ... at B. Braun: "B. Braun serves customers in ...
Breaking Medicine News(10 mins):Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... say the drug clodronate is an effective treatment for patients ... studied more than 1,000 patients // with breast cancer. Patients ... day or a placebo for five years. ,Results showed ... to their bones. Fifty-one of these patients were treated with ...
... identified a protein that essentially blocks HIV replication, in ... is not as effective at stopping HIV, say the ... of Nature. The team, headed by Joseph Sodroski, is ... Infectious Diseases (NIAID). ,"Identification of this HIV-blocking ...
... According to recent findings researchers say the risks and ... to be re-evaluated.// Researchers from Sweden studied more than ... of age. Participants had their intellectual capacity tested at ... school attendance records for the young men. ,Results ...
... pressure at home may lead to fewer blood pressure ... at patients’ homes to conventional doctors’ office measurements of ... patients with a diastolic blood pressure reading of 95 ... offices were included for the study. All of the ...
... a new treatment can now help chronic chest pain sufferers ... other antianginal medications it was found to improve the total ... ,Ranolazine is currently under review by the FDA. ... angina were randomly assigned to receive a placebo or one ...
... a non-surgical technique used to eliminate alternate pathways ... // Researchers now say that congestive heart failure ... of irregular heart rhythm experience significant improvement ... catheter ablation. ,58 patients with congestive heart ...
Cached Medicine News:
(Date:7/29/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.476 ... or $(0.02) per share. These results compare to net ... $311 thousand, or $(0.04) per share, in the year-ago ...
(Date:7/28/2014)... , July 28, 2014 Pharmacyclics, Inc. (the "Company") ... hold a conference call and audio webcast to discuss financial ... Market closes on Thursday, July 31, 2014 at 4:30 p.m. ... Date: July 31, 2014 Time: 4:30 PM ... 303-7908 International: (678) 373-0875 A webcast replay will ...
(Date:7/28/2014)...  MiMedx Group, Inc. (NASDAQ: MDXG ), an integrated ... bioimplants processed from human amniotic membrane, announced today its results ... include: , Revenue exceeds upper end of ... million , Quarter-over-quarter revenue grew by ... 181% over Q2 2013 and 40% sequentially over Q1 2014 ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18
... Phase II Trial Initiated by Myriad For Azixa(TM), ... and OMX Nordic Exchange: EPCT) today reported on ... agent,licensed by the Company to Myriad Genetics, Inc. ... agreement. (Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) ...
... DNDN ) today announced publication of results ... active cellular immunotherapy, in the,August 20 issue of ... safety profile, immune response and clinical activity of ... failed standard,therapy. "In addition to demonstrating that ...
Cached Medicine Technology:EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 2EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 3EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 4EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 5Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4
... The new Guidant VASOVIEW® ... to deliver a new level ... harvesting for both the saphenous ... simultaneous cut-and-seal capability, it lets ...
...
... Now rapid intrapartum or antepartum GBS results ... versus 2 days. This revolutionary in vitro diagnostic ... designed to be run in the clinical lab ... and delivery nurses 24 hours a day, ...
... contains primers and a FAM-labeled probe that is ... the mecA gene. In addition, this ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
Medicine Products: